Not possible to specify

441 trials 102 recruiting

Filter these 441 trials by phase, country and sponsor.

Open in Search →

Efficacy and Safety of Oral Midazolam for Providing Care to Patients Who Refuse Treatment and Have Moderately Severe to Severe Neurocognitiv… Ended

2023-510277-33-00 Neurocognitive Disorders and Agitation in Older Adults 4 2026-04-21
Multiple-Dose Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions. Ended

2025-522627-10-00 No medical condition. 2 2026-04-20
Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fed Conditions. Ended

2025-522624-27-00 No medical condition. 2 2026-04-15
KF2025#1 trial: Ketamine, cannabidiol and cobicistat interaction study Ended

2025-523817-27-00 Terveet vapaaehtoiset tutkittavat 2 2026-03-05
The effect of losartan on cephalexin Ended

2025-525059-23-00 healthy volunteers 3 2026-03-04
A study in healthy people or otherwise healthy with overweight or obesity to compare 2 formulations of survodutide given in different ways, … Ended

2024-519614-30-00 Healthy volunteer trial 3 2026-03-02
A clinical study to investigate the safety, tolerability and pharmacokinetic profile of single ascending concentrations of OPT101 in periton… Ended

2025-522966-61-00 Chronic kidney disease 1 2026-02-16
A single dose, randomized, double-blind 2-arm parallel-group study to compare the pharmacokinetics, immunogenicity, and safety for PB016 ver… Ended

2025-522534-31-00 Not applicable, healthy volunteers 3 2026-01-27
A trial to learn how well different doses of andexanet alfa work and how they affect blood clotting throughout the body in healthy adults wh… Ended

2025-522513-30-00 Healthy Volunteers 3 2026-01-12
A study in healthy people to compare how 2 different formulations of survodutide are taken up by the body Ended

2025-522325-35-00 Healthy volunteer trial 3 2025-10-27
MULTICENTER, RANDOMIZED, BLIND AND CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY IN THE CORRECTION OF DEFICIT IN SUBJECTS WI… Ended

2024-514528-17-00 Severe vitamin D deficiency 6 2025-09-15
A research study comparing how well different doses of the medicine NNC0519-0130 can reduce kidney damage in people living with chronic kidn… Ended

2024-510846-15-00 Chronic Kidney Disease, with or without Type 2 diabetes 4 2025-04-14
Clinical trial to evaluate effectiveness and cost-effectiveness of pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretra… Ended

2024-516596-32-00 Kidney transplant 6 2025-03-31
POEM Study Ended

2024-519386-21-01 Gestational diabetes mellitus 5 2025-01-29
Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusion Ended

2022-502878-16-00 Acute ischemic strokes with incomplete reperfusion 5 2025-01-23
A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab… Ended

2024-511650-50-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-01-17
Safety and efficacy of the FTP-002 / FTP-501 combination in the treatment of glabellar lines. Ended

2023-507249-27-00 glabellar lines. 7 2024-11-26
A study organ preservation with Custodiol-N solution compared with Custodiol solution in liver trasnplantation Ended

2024-518174-13-00 Liver transplantation 5 2024-10-24
VALSARTAN TREATMENT COMPARED IN RENAL TRANSPLANT RECIPIENTS WITH SIGNS OF POST TRANSPLANT GLOMERULOPATHY Ended

2024-518723-30-01 Renal transplant patients 6 2024-10-16
An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Pa… Ended

2024-511212-24-00 Advanced solid tumors 9 2024-10-07
Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease Ended

2023-505890-34-00 Autosomal dominant polycystic kidney disease 6 2024-06-27
Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone… Ended

2023-508310-41-00 Multiple myeloma 4 2024-06-26
Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322) Ended

2022-502010-85-00 Non-Squamous Non-Small Cell Lung Cancer 9 2023-12-20
A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants with Prodromal and Early Manife… Ended

2023-503928-10-00 Prodromal and Early Manifest Huntington’s Disease 4 2023-02-01